Harvard Bioscience Inc. said it will spin off its regenerative medicine device business through an IPO next year. The Holliston company will seek to raise $20 million by taking public its subsidiary, Harvard Apparatus Regenerative Technology, which is developing parts for “bioartificial” organs such as replacement tracheas. CEO Chane Graziano said it has become too complicated to manage the research tool business and clinical-stage regenerative device unit together.
Harvard Bioscience will spin off subsidiary
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week